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The study of  cell proliferation is a useful tool in the fi elds of  toxicology, pathophysiology 
and pharmacology. Cell proliferation and its degree can be evaluated using 5-bromo-2′-
deoxyuridine which is incorporated into the newly synthesized DNA. The aim of  this 
study was the optimization of  subcutaneous application of  5-bromo-2′-deoxyuridine 
implantation for continuous and persistent marking of  proliferating cells in the rat 
forestomach. 3-tert-Butyl-4-hydroxyanisole was used as the agent that ensures cell 
proliferation. In order to determine the optimal dose for proliferating cells labeling, 
5-bromo-2′-deoxyuridine doses of  50 mg, 100 mg, 200 mg or 350 mg were implemented 
2 days prior to sacrifi ce by fl at-faced cylindrical matrices. Immunohistochemical analysis 
using 5-bromo-2′-deoxyuridine in situ detection kit was performed for the detection 
of  5-bromo-2′-deoxyuridine labeled cells. The results showed that for adult rats, 
the optimum 5-bromo-2′-deoxyuridine dose is 200 mg per animal for subcutaneous 
application. The here described manner of  5-bromo-2′-deoxyuridine in vivo labeling 
provides a simple, effi cient, and reliable method for cell labeling, and at the same 
minimizes stress to animals.
Key words: 5-bromo-2′-deoxyuridine, 3-tert-Butyl-4-hydroxyanisole, BrdU in vivo 
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INTRODUCTION
The rat stomach is morphologically and physiologically different from the human 
and the stomach of  other laboratory animals. Its proximal nonglandular part, i.e. the 
forestomach, constitutes approximately 60% of  this organ and it consists of  a stratifi ed 
squamous epithelium which is constantly renewing [1]. Therefore, the balance between 
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cell proliferation and cell loss by apoptosis is necessary for the normal functioning of  
the forestomach.
The main function of  the forestomach is to serve as a food reservoir leading to long-
term exposure to xenobiotics, which makes it a good target tissue in cell proliferation 
studies [2]. Numerous xenobiotics lead to disturbed tissue homeostasis, which may 
result in cell loss, consequent tissue atrophy and failure, or excessive cell proliferation 
and eventually carcinogenesis, which makes cell proliferation studies a very important 
and useful tool.
The forestomach is sensitive to tissue damage by non-genotoxic compounds like the 
food additive 3-tert-Butyl-4-hydroxyanisole (BHA). BHA is commonly used as an 
antioxidant food additive in fats and oils (E321). There is evidence that prolonged 
exposure to this agent induces hyperplasia that eventually results in carcinomas in the 
rat forestomach [3,4]. On basis of  such data the International Agency for Research on 
Cancer (IARC) has classifi ed BHA as a B2 carcinogen [5]. 
The study of  cell proliferation is a useful tool in the fi elds of  toxicology, pathophysiology 
and pharmacology [6,7]. Cell proliferation and its degree can be evaluated using 
5-bromo-2′-deoxyuridine (BrdU) which is incorporated into the newly synthesized 
DNA, during the S phase of  the cell cycle [8]. BrdU is a thymine analogue which 
pairs with purine bases with different affi nity depending on its isoform, i.e. in the 
keto form it pairs with adenine, whereas in the enol form it pairs with guanine [9]. 
This method allows the quantifi cation of  newly generated cells and therefore enabled 
the study of  the effects of  xenobiotics on cell proliferation, death and migration 
behavior in a quantitative manner [10]. Pharmacokinetics studies showed that the most 
commonly used doses of  BrdU (50-100 mg/kg) and routes of  administration such as 
intravenous and intraperitoneal (i.v. and i.p., respectively) are suitable for use in pulse-
label experiments. BrdU is quickly degraded in vivo, and its half-life is approximately 
60 min both in the blood serum and in various tissues [11,12]. For continuous-label 
studies a prolonged and continuous exposure to the labeling agent must be achieved.
Although several administration routes of  BrdU have already been described in order 
to mark proliferating cells, accurate monitoring of  proliferation in tissues that need 
more time for renewal requires further optimization. Furthermore, the effects of  
subacute or chronic exposure to proliferating agents could be observed more precisely 
with continuous-label methods. The aim of  this study was to optimize a subcutaneous 
BrdU implantation for continuous and persistent marking of  proliferating cells. As the 
agent that ensures cell proliferation we used 3-tert-Butyl-4-hydroxyanisole (BHA) [3]. 
MATERIALS AND METHODS 
Animals
All procedures on animals were approved by the Ethical Committee for the Use of  
Laboratory Animals, University of  Belgrade, Vinča Institute of  Nuclear Sciences 
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(Number of  Ethical Committee approval DD1/15), according to the guidelines of  
the EU registered Serbian Laboratory Animal Science Association (SLASA).
Seven weeks old male Wistar rats (250±10g), obtained from the local colony and 
separate litters, were maintained under standard conditions: group-housed (4 per cage) 
with free access to food (commercial pellet) and tap water, regular 12 h light/12 h dark 
cycle and constant temperature (21 ± 2°C) and humidity.
Treatment and surgical procedure
The experimental design is presented in Table 1. On the fi rst day of  the experiment, 
animals were randomly divided into two main groups: (I) control animals; (II) rats 
intragastrically intubated (reusable stainless steel feeding needle, 16-G4”, 3 mm ball 
diameter, Cadence Inc., Staunton, Virginia, USA), three times per week for 4 weeks 
with butylated hydroxyanisole (BHA) (2% BHA in the powdered feed) (Sigma-Aldrich 
Co., Saint Louis, Missouri, USA). Although it has been reported that rat pellets may 
be enriched with BHA and the animals consume this food readily [3], animals refused 
to consume pellets prepared in this way, rapidly losing their body mass, thus forcing 
us to feed the animals by intubation a mixture of  pellets with BHA. Additionally, two 
days prior to sacrifi ce animals were subdivided into experimental groups according to 
implemented BrdU doses: 50 mg, 100 mg, 200 mg or 350 mg (n = 4 per experimental 
group). Animal weight at this point was 372 ± 21 g. Flat-faced cylindrical matrices 
containing 50 mg of  BrdU (Sigma-Aldrich Co., St. Louis, USA) with a diameter of  
5.6 mm were prepared by a direct compression technique using an eccentric tablet 
press (Korsch EK-0, Korsch, Berlin, Germany). BrdU matrices were subcutaneously 
implanted in the dorsal neck region under 5% chloral hydrate (400 mg/kg, Sigma-
Aldrich Co., St. Louis, USA) anesthesia. 
Table 1. Number of  BrdU positive cells in the forestomach epithelium treated with different 
doses of  BrdU.
Groups Doses of  BrdU (mg) Number of  cells/mm2
Control 200 18.24 ± 8.4
BHA 50  16.95 ± 6.1a
BHA 100       51.07 ± 25.0b
BHA 200    67.63 ± 21.5*
BHA 350    75.27 ± 21.0*
The results are represented as mean ± SD
*p<0.001 BHA treated vs. control animals; ap<0.01 BHA treated animals which received 
50 mg vs. animals which received 100, 200 and 350 mg BrdU; bp<0.01 BHA treated animals 
which received 100 mg BrdU vs. animals which received 200 and 350 mg BrdU.
During post-operative recovery, physical health condition of  all rats was closely 
monitored on a daily basis.
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Tissue preparation
The animals were sacrifi ced by decapitation, the stomachs removed, the forestomach 
separated, cut along the minor curvature, washed in 0.9% aqueous sodium chloride, 
spread on paraffi n substrate with pins and covered with 10% neutral buffered formalin 
for one week. After fi xation, the tissues were dehydrated in a series of  ethanol solutions 
(70%, 96% and 100%) and xylene, and then embedded into paraffi n blocks. Paraffi n 
tissue blocks of  the forestomach were cut transversely into serial sections 5 μm in 
thickness. 
Two consecutive sections, with ten levels, ranging from 250 μm between each level, 
were taken for: a) histochemical staining with hematoxylin and eosin for histological 
analysis and b) immunohistochemical staining for the detection of  BrdU incorporation 
into DNA, i.e. analysis of  cell proliferation. The analysis was done on light microscope 
Olympus AX70 with  10 × and 20 × objective magnifi cation. 
Immunohistochemical procedure
After deparaffi nization in xylene, treatment with descending concentrations of  
alcohols, and rehydration in distilled water the forestomach sections were stained 
immunohistochemically according to the manufacturer’s instructions (BrdU in situ 
detection kit, BD Pharmingen, New Jersey, USA). The procedure is based on the 
use of  a directly biotinylated monoclonal antibody against BrdU, streptavidin-HRP 
solution as the detection system and 3,3’-diaminobenzidine (DAB, BD Pharmingen, 
New Jersey, USA) as a chromogen for visualization of  BrdU incorporation. 
Forestomach tissue sections not treated with the primary antbody were used as the 
control. Counterstaining with Mayer’s hematoxylin (Merck, Billerica, MA, USA) was 
used for the analysis on a light microscope. 
Morphometry
Quantifi cation of  labeled (BrdU+) cells in the forestomach epithelium was performed 
using a computer-supported imaging system connected to a light microscope (Olympus 
AX70) with an objective magnifi cation of  10 ×. The epithelial area was calculated 
according to the following formula: 
P = p × d2/106, 
Where, P is the surface area, p is the number of  grid points in the epithelium, and d is 
the size of  the square network at a magnifi cation of  200 (10 × objective). The number 
of  BrdU+ cells/mm2 of  epithelium (N) was calculated according to the formula:
N = n/P:
Here, n is the number of  BrdU+ cells on the analyzed surface, and P is the analyzed 
surface area of  epithelium. The number of  proliferating (BrdU+) cells was expressed 
per mm2 of  epithelium.
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Statistical analysis 
The results are expressed as the mean ± SD. Values were compared using the 
nonparametric Mann–Whitney U test in the program SPSS 10 for Windows. 
Differences at p<0.05 were accepted as signifi cant.
RESULTS
The results showed the presence of  proliferating  BrdU labeled cells (BrdU+) in the 
basal layer of  the rat forestomach epithelium of  the control and BHA treated animals 
(Figure 1). BHA treatment (2% in the powdered feed, three times per week) leads to 
Figure 1. Immunohistochemical expression of  BrdU positive cells in the rat forestomach 
epithelium. (A) Negative control. (B) Control rats treated with 200 mg BrdU. (C-F) Rats 
treated with the same doses of  BHA and different doses of  BrdU for 2 days: (C) 50 mg of  
BrdU, (D) 100 mg of  BrdU, (E) 200 mg of  BrdU and (F) 350 mg of  BrdU. Scale bar 200 μm 
(right angle down). Legend: arrow - basal layer; arrow head – zone of  the granulosa.
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the proliferation of  cells of  the basal layer of  the epithelium, while the number of  
BrdU+ cells depends on the dosage of  BrdU (Figure 1C-F). BHA-treated animals which 
received 50 mg of  BrdU had proliferating cells mainly present in the basal layer of  the 
epithelia and rarely in the zone of  the granulosa (Figure 1C). In the treated animals, 
which had BrdU administered at a concentration of  100 and 200 mg a signifi cant 
increase of  BrdU+ cells could be seen in the basal layer of  the epithelium arranged in 
several layers (Figure 1D-E). BHA treated animals which received 350 mg of  BrdU 
had, in addition to the presence of  labeled cells in the basal layer of  the epithelium, an 
increased presence of  the BrdU+ cells in the zone of  the granulosa (Figure 1F).
Table 1. shows the number of  BrdU+ cells in the epithelium of  the control and BHA 
treated animals in which different doses of  BrdU were administered. It was shown 
that in animals treated with  BHA after the application of  50 mg of  BrdU, the number 
of  BrdU+ cells was not signifi cantly changed in comparison to the control animals. 
However, application of  higher doses of  BrdU (100, 200 and 350 mg) signifi cantly 
increased the number of  BrdU+ cells in relation to the control and the group receiving 
50 mg of  BrdU. It was also shown that application of  high doses of  BrdU (200 and 
350 mg) signifi cantly increased the number of  labeled cells in comparison to a dose of  
100 mg of  BrdU. There were no signifi cant changes in the number of  BrdU+ cells in 
the animals that received 200 mg compared to animals that received 350 mg of  BrdU.
DISCUSSION
The use of  BrdU for studying cell proliferation in various tissues is not of  a recent 
date. The gut, kidney and liver were among the fi rst analyzed tissues [13]. There are 
many described manners for BrdU in vivo labeling, treatment duration, methods of  
application and dose regimens. Therefore, the main objective of  this study was to 
determine the optimum dose and application method of  BrdU required for successful 
monitoring of  cell proliferation in the rat forestomach for pharmacological and 
toxicological investigations. The rat forestomach was the target tissue considering its 
function as a storage organ. It serves as a holding compartment, so the tissue suffers 
prolonged exposure to xenobiotics [2]. In our study, butylated hydroxyanisole (BHA) 
was used as a proven cell proliferation agent [3]. Agents like BHA cause chronic 
infl ammation or local irritation of  the forestomach mucosa eventually leading to cell 
proliferation and hyperplasia [14]. In vivo labeling of  DNA using BrdU should provide 
simple administration with minimal stress to animals and adequate dose regimens to 
ensure confi dent marking of  cells.
Cantoreggi et al. (1993) applied BrdU via subcutaneous (s.c.) implantation of  osmotic 
minipumps for proliferation studies [3]. Staszkiewicz et al. (2009) injected BrdU i.p. in 
mice twice daily for three consecutive days; Zhang et al. (2015) also used i.p. injection 
of  BrdU twice a day at 2 h intervals over four consecutive days, whereas Ševc et al. 
(2015) administered BrdU dissolved in drinking water over a prolonged period of  
time [15-17]. While Staszkiewicz et al .(2009) and Zhang et al. (2015) concluded that 
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i.p. injections of  BrdU is appropriate as a biomarker of  their study, Ševc et al. (2015) 
concluded that oral administration of  BrdU does not provide accurate information 
about the number of  proliferating cells in target tissues [15-17]. Erben et al. (2008) 
reported subcutaneous implementation of  BrdU pellets for 3 and 7 weeks exposure, 
however long term exposure resulted in BrdU toxicity accompanied with decreased 
labeling effi ciency over time, thus the precise monitoring of  cell proliferation can 
not be achieved in this manner [18]. Weghorst et al. (1991) showed that s.c. BrdU 
administration for 4 days provides more accurate data of  the true proliferative 
scenario in cell kinetic studies in contrast to the pulse-labeled approach [19]. A further 
increase in treatment duration decreased the number of  labeled cells. Comparative use 
of  osmotic minipumps and slow-release BrdU pellets showed that nuclear labeling 
was very similar with both techniques. We found that implementation of  BrdU 
matrices subcutaneously, two days prior to sacrifi ce provided a slow and continuous 
release similar to the effect of  osmotic minipumps. In contrast to osmotic minipumps 
administration of  BrdU matrices is simple, the wound is minimal and sutured with one 
surgical stitch.
The concentration of  BrdU has an effect on cell proliferation across a wide range 
of  doses depending on the way of  application (40–480 mg/kg for i.p., and up to 2.5 
g/kg for subcutaneous application) as reported in the literature [19,20]. Our study 
demonstrated that s.c. application of  200 mg of  BrdU per animal is optimal for 
adequate labeling of  proliferating cells in adult rats. 
CONCLUSIONS
Our results showed that doses of  50 and 100 mg of  BrdU administered subcutaneously 
are not suffi cient for adequate labeling of  proliferating cells of  the rat forestomach. 
Subcutaneous administration of  200 mg of  BrdU per animal (i.e. on average 540 mg 
of  BrdU/kgBW) is optimal for labeling proliferating cells, whereas a further increase 
in BrdU dose does not have an impact on the number of  labeled cells. Due to the fast 
turnover of  rat forestomach epithelium the duration of  BrdU exposure of  two days 
gave suffi cient results.
Evidently, trying to standardize the dose and application method of  BrdU should 
simplify cell proliferation studies. At least in the case of  adult rats, it may be accepted 
that the optimum BrdU dose is 200 mg per animal for s.c. application. These results 
do not provide only certain and unambiguous immunohistochemical results, but also 
reduces stress to animals as multiple injections are obliterated and elaborate minipumps 
are not required.
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PRAĆENJE ĆELIJSKE PROLIFERACIJE – OPTIMIZACIJA 
METODE ZA IN VIVO OBELEŽAVANJE DNK ĆELIJA ŽELUCA 
PACOVA
JOKSIĆ Gordana, MIĆIĆ Mileva, FILIPOVIĆ Jelena, DRAKULIĆ Dunja, 
STANOJLOVIĆ Miloš, ČALIJA Bojan, VALENTA ŠOBOT Ana, DEMAJO 
Miroslav, NILSSON Robert
Praćenje ćelijske proliferacije je važno za istraživanja u oblasti toksikologije, pa-
tofi ziologije i farmakologije. Kao pokazatelj stepena ćelijske proliferacije koristi 
se 5-bromo-2′-deoksiuridin koji se ugrađuje u novosintetisanu DNK ćelija u S fazi 
ćelijskog ciklusa. Cilj ove studije je optimizacija potkožne implantacije 5-bromo-2′-
deoksiuridina za kontinuirano i dugotrajno obeležavanje ćelija u deobi na modelu 
nežlezdanog dela  želuca pacova. Ćelijska proliferacija indukovana je 3-tert-Butil-4-hi-
droksianizolom. 5-bromo-2′-deoksiuridin u dozama od 50 mg, 100 mg, 200 mg i 350 
mg je implantiran dva dana pre žrtvovanja u formi pljosnatih cilindričih matrica u 
cilju utvrđivanja optimalne doze za obeležavanje ćelija u deobi. Imunohistohemijska 
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analiza 5-bromo-2′-deoksiuridin in situ detekcionim kitom je korišćena za kvantifi -
kaciju 5-bromo-2′-deoksiuridin obeleženih ćelija. Rezultati su pokazali da je za odrasle 
pacove optimalna doza 5-bromo-2′-deoksiuridina za potkožnu implantaciju 200 mg 
po životinji. Opisani način 5-bromo-2′-deoksiuridin in vivo obeležavanja omogućava 
jednostavan, efi kasan i pouzdan način obeležavanja ćelija sa minimalnim stresom za 
životinje.
